公开(公告)号：JP2012111760A

公开(公告)日：2012-06-14

申请号：JP2011288226

申请日：2011-12-28

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C237/24 ,  A61K31/16 ,  A61K31/165 ,  A61K31/18 ,  A61K31/196 ,  A61K31/277 ,  A61K31/40 ,  A61K31/41 ,  A61K31/42 ,  A61K31/44 ,  A61K31/5375 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08 ,  C07D295/08 ,  C07D295/22 ,  C07D401/04

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: PROBLEM TO BE SOLVED: To provide adamantyl derivatives as an 11-β-hydroxysteroid dehydrogenase (HSD) 1, whose inhibition prevents or decreases the tissue specific amplification of glucocorticoid action thus imparting beneficial effects on blood pressure and glucose- and lipid-metabolism.SOLUTION: Compounds are used which are inhibitors of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-β-hydroxysteroid dehydrogenase Type 1 enzyme, e.g. acylamino-substituted adamantane carboxylic amides, for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 要解决的问题：提供作为11-β-羟基类固醇脱氢酶（HSD）1的金刚烷基衍生物，其抑制可以防止或减少糖皮质激素作用的组织特异性扩增，从而赋予血压和葡萄糖 - 和脂质 - 代谢。 解决方案：使用化合物，其是11-β-羟基类固醇脱氢酶1型酶的抑制剂。 本发明还涉及11-β-羟基类固醇脱氢酶抑制剂1型酶的用途，例如， 用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及由过度的糖皮质激素作用介导的其它疾病和病症的酰氨基取代的金刚烷羧酸酰胺。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：JP2013209377A

公开(公告)日：2013-10-10

申请号：JP2013086296

申请日：2013-04-17

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BROWMAN KAITLIN E ,  ROHDE JEFFREY ,  JACOBSON PEER B ,  BRUNE MICHAEL E ,  RUETER LYNNE E ,  WANG JIAHONG ,  LINK JAMES T ,  ROBERT S BITNER ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  MADAR DAVID J ,  PATEL JYOTI ,  PLIUSHCHEV MARINA ,  SHUAI QI ,  SORENSEN BRYAN ,  WICKE KARSTEN ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K45/00 ,  A61K31/16 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: PROBLEM TO BE SOLVED: To provide a therapeutic agent for a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, and schizophrenia.SOLUTION: A pharmaceutical composition includes an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme activity represented by formula.

Abstract translation: 要解决的问题：为患有与衰老和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者提供治疗剂，其包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病 （AD），轻度认知障碍，老年性痴呆，艾滋病痴呆，神经变性和精神分裂症。解决方案：药物组合物包括有效量的由式表示的11-＆bgr-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：JP2009046464A

公开(公告)日：2009-03-05

申请号：JP2007241117

申请日：2007-09-18

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BROWMAN KAITLIN E ,  ROHDE JEFFREY ,  JACOBSON PEER B ,  BRUNE MICHAEL E ,  RUETER LYNNE E ,  WANG JIAHONG ,  LINK JAMES T ,  ROBERT S BITNER ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  MADAR DAVID J ,  PATEL JYOTI ,  PLIUSHCHEV MARINA ,  SHUAI QI ,  SORENSEN BRYAN ,  WICKE KARSTEN ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K31/165 ,  A61K31/496 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D213/74

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating patients with diabetes-, aging- and neurodegeneration-related central-nervous-system disorders and deletions including ordinary attention-deficit disorders, attention-deficit hyperactivity disorders (ADHD), Alzheimer's disease (AD), mild cognitive damage, senile dementia, AIDS dementia, neurodegeneration and schizophrenia. SOLUTION: The pharmaceutical composition for treating glucocorticoid-related central-nervous-system disorders contains a selective inhibitor for 11-β-hydroxysteroid dehydrogenase 1-type enzyme activity. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 待解决的问题：提供一种用于治疗患有糖尿病，老化和神经变性相关的中枢神经系统疾病和缺失的药物组合物，包括普通注意力缺陷障碍，注意力缺陷多动障碍（ADHD） 阿尔茨海默病（AD），轻度认知损伤，老年痴呆，艾滋病痴呆，神经变性和精神分裂症。 解决方案：用于治疗糖皮质激素相关中枢神经系统疾病的药物组合物含有11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：WO2006074330A3

公开(公告)日：2007-01-25

申请号：PCT/US2006000402

申请日：2006-01-05

Applicant: ABBOTT LAB ,  ROHDE JEFFREY J ,  SHUAI QI ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  YEH VINCE S ,  KURUKULASURIYA RAVI

Inventor： ROHDE JEFFREY J ,  SHUAI QI ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  YEH VINCE S ,  KURUKULASURIYA RAVI

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  A61P3/10 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2006074244A3

公开(公告)日：2006-09-28

申请号：PCT/US2006000210

申请日：2006-01-05

Applicant: ABBOTT LAB ,  PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2009026422A2

公开(公告)日：2009-02-26

申请号：PCT/US2008073830

申请日：2008-08-21

Applicant: ABBOTT LAB ,  BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

Inventor： BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K31/495 ,  A61K31/44

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-ß-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract translation: 用于治疗患有与糖尿病相关的中枢神经系统与衰老和神经变性有关的障碍和缺陷的患者的方法，其包括一般的注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年痴呆症，艾滋病痴呆症，神经变性，抑郁症和精神分裂症的方法，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：NZ555966A

公开(公告)日：2011-03-31

申请号：NZ55596606

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

Abstract: The disclosure relates to adamantine-carboxamide derivative compounds of formula (I) which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, wherein the variables are as defined in the specification. The disclosure further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：MX2009013213A

公开(公告)日：2010-03-30

申请号：MX2009013213

申请日：2008-06-04

Applicant: ABBOTT LAB

Inventor： KALVIN DOUGLAS M ,  WANG LU ,  GASIECKI ALAN F ,  GRACIAS VIJAYA J ,  AKRITOPOULOU-ZANZE IRINI ,  LI BIQIN ,  PATEL JYOTI R ,  SHUAI QI ,  TURNER SEAN C ,  DJURIC STEVAN W ,  BAKKER MARGARETHA ,  VASUDEVAN ANIL ,  MICHMERHUIZEN MELISSA J ,  SARRIS KATHY ,  HOBSON ADRIAN ,  TEUSCH NICOLE ,  MACK HELMUT ,  WAKEFIELD BRIAN D ,  JOHNSON ERIC T ,  KOVAR PETER J ,  LONG ANDREW J ,  MOORE NIGEL ST JOHN ,  GEORGE DAWN ,  FRANK KRISTINE

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: La presente invención se refiere a compuestos de la fórmula (I) o sales farmacéuticamente aceptables, en donde A, R1, R2, R3 y m, son como se definieron en la descripción. La presente invención se refiere también a métodos para elaborar los compuestos, y composiciones que contienen los compuestos los cuales son útiles para inhibir las cinasas tales como Glicógeno Cintaza cinasa 3 (GSK-3), Rho cinasa (ROCK), Janus Cinasas (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 y nek 2.

公开(公告)号：CA2568241A1

公开(公告)日：2005-11-17

申请号：CA2568241

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  WODKA DARIUSZ ,  SHUAI QI ,  PATEL JYOTI R ,  LINK JAMES T ,  PLIUSHCHEV MARINA A

IPC: C07D213/06 ,  A61K31/44 ,  A61K31/445 ,  C07C237/04 ,  C07C237/24 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：ZA200908624B

公开(公告)日：2015-08-26

申请号：ZA200908624

申请日：2009-12-04

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： FRANK KRISTINE ,  GEORGE DAWN ,  ST JOHN MOORE NIGEL ,  VASUDEVAN ANIL ,  LONG ANDREW J ,  KOVAR PETER J ,  JOHNSON ERIC T ,  TEUSCH NICOLE ,  BAKKER MARGARETHA ,  MICHMERHUIZEN MELISSA J ,  KALVIN DOUGLAS M ,  SARRIS KATHY ,  GRACIAS VIJAYA J ,  GASIECKI ALAN F ,  WAKEFIELD BRIAN D ,  AKRITOPOULOU-ZANZE IRINI ,  HOBSON ADRIAN D ,  WANG LU ,  PATEL JYOTI R ,  SHUAI QI ,  TURNER SEAN C ,  DJURIC STEVAN W ,  MACK HELMUT ,  LI BIQIN